Effectiveness of Prophylactic Coagulation Factor Replacement Therapy in Patients with Severe Hemophilia A in Taiwan – A Population-Based Study

References

• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26(S6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Manco-Johnson M. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice. Haemophilia. 2007;13(Suppl 2):4–9. doi:10.1111/j.1365-2516.2007.01499.x
   PubMed Web of Science ®Google Scholar
• O’Hara J, Sima CS, Frimpter J, Paliargues F, Chu P, Presch I. Long-term outcomes from prophylactic or episodic treatment of haemophilia A: a systematic review. Haemophilia. 2018;24(5):e301–e311. doi:10.1111/hae.13546
   Web of Science ®Google Scholar
• Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013;11(6):1119–1127. doi:10.1111/jth.12202
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–544. doi:10.1056/NEJMoa067659
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xiao J, Yang R, et al. Efficacy of standard prophylaxis versus on-demand treatment with Bayer’s sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A. Pediatr Hematol Oncol. 2017;34(3):138–148. doi:10.1080/08880018.2017.1313921
   Web of Science ®Google Scholar
• Andersson NG, Auerswald G, Barnes C, et al. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment. Br J Haematol. 2017;179(2):298–307. doi:10.1111/bjh.14844
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Soucie JM, Gill JC. Joint outcomes committee of the universal data collection USHTCN. prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129(17):2368–2374. doi:10.1182/blood-2016-02-683169
   Web of Science ®Google Scholar
• Dunn AL, Abshire TC. Current issues in prophylactic therapy for persons with hemophilia. Acta Haematol. 2006;115(3–4):162–171. doi:10.1159/000090930
   Web of Science ®Google Scholar
• O’Mahony B, Noone D, Prihodova L. Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries. Haemophilia. 2015;21(4):436–443. doi:10.1111/hae.12720
   PubMed Web of Science ®Google Scholar
• Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med. 2013;4:49–56. doi:10.2147/jbm.S43734
   PubMedGoogle Scholar
• National Health Insurance Administration Ministry of Health and Welfare. National health insurance reimbursement guideline for hematological drugs in Taiwan; 2014. Available from: https://www.nhi.gov.tw/Content_List.aspx?n=E70D4F1BD029DC37&topn=3FC7D09599D25979. Accessed September 19, 2021.
   Google Scholar
• Hsieh MH-C, Chiou -S-S, Liao T-C, Kao Yang Y-H, Lai E-C-C. Trends in coagulation factor replacement therapy and medical costs in patients with haemophilia in Taiwan: a population-based, 15-year analysis. Haemophilia. 2021;27(2):e187–e193. doi:10.1111/hae.14250
   Web of Science ®Google Scholar
• Ingerslev J, Lethagen S, Hvitfeldt Poulsen L, et al. Long-standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison of age-matched Danish and Russian patients. Haemophilia. 2014;20(1):58–64. doi:10.1111/hae.12242
   Web of Science ®Google Scholar
• Oldenburg J, Zimmermann R, Katsarou O, et al. Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand. Haemophilia. 2015;21(2):171–179. doi:10.1111/hae.12539
   Web of Science ®Google Scholar
• Hilliard P, Zourikian N, Blanchette V, et al. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. J Thromb Haemost. 2013;11(3):460–466. doi:10.1111/jth.12113
   Web of Science ®Google Scholar
• Meng L, Zhuang J, Sun X, et al. FVIII剂量对青少年重型血友病A的关节结构与功能的影响 43例前瞻性队列研究中期随访报告 [Effect of FVIII doses on joint structure and function in adolescents with severe hemophilia A: mid-term results of a prospective cohort study]. Nan Fang Yi Ke Da Xue Xue Bao. 2021;41(4):536–542. Chinese. doi:10.12122/j.issn.1673-4254.2021.04.08
   Google Scholar
• Nagae C, Yamashita A, Ashikaga T, et al. A cohort study of the usefulness of primary prophylaxis in patients with severe haemophilia A. Int J Hematol. 2016;104(2):208–215. doi:10.1007/s12185-016-2005-3
   Web of Science ®Google Scholar
• Hsieh CY, Su CC, Shao SC, et al. Taiwan’s national health insurance research database: past and future. Clin Epidemiol. 2019;11:349–358. doi:10.2147/clep.S196293
   PubMed Web of Science ®Google Scholar
• Jadhav U, Mukherjee K. Assessment of healthcare measures, healthcare resource use, and cost of care among severe hemophilia A patients in Mumbai region of India. J Postgrad Med. 2018;64(3):138–144. doi:10.4103/jpgm.JPGM_701_16
   PubMed Web of Science ®Google Scholar
• Croteau SE, Cook K, Sheikh L, et al. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. J Manag Care Spec Pharm. 2021;27(3):316–326. doi:10.18553/jmcp.2021.27.3.316
   PubMed Web of Science ®Google Scholar
• Oladapo AO, Lu M, Walsh S, O’Hara J, Kauf TL. Inhibitor clinical burden of disease: a comparative analysis of the CHESS data. Orphanet J Rare Dis. 2018;13(1):198. doi:10.1186/s13023-018-0929-9
   Web of Science ®Google Scholar
• Chen Y-C, Chang C-Y, Cheng S-N, et al. Evolution of congenital haemophilia care in Taiwan. J Formos Med Assoc. 2021;2021. doi:10.1016/j.jfma.2021.07.017
   Web of Science ®Google Scholar
• Franklin JM, Shrank WH, Pakes J, et al. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Med Care. 2013;51(9):789–796. doi:10.1097/MLR.0b013e3182984c1f
   PubMed Web of Science ®Google Scholar
• Ds Nagin. Analyzing developmental trajectories: a semiparametric, group-based approach. Psychol Methods. 1999;42(2):139–157.
   Web of Science ®Google Scholar
• Nagin DS, Nagin D, Nagin TH. Group-Based Modeling of Development. Harvard University Press; 2005.
   Google Scholar
• Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109–138. doi:10.1146/annurev.clinpsy.121208.131413
   PubMed Web of Science ®Google Scholar
• Gupta S, Siddiqi A-EA, Soucie JM, et al. The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia. Br J Haematol. 2013;161(3):424–433. doi:10.1111/bjh.12267
   Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi:10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• Jackson JW, Schmid I, Stuart EA. Propensity scores in pharmacoepidemiology: beyond the Horizon. Curr Epidemiol Rep. 2017;4(4):271–280. doi:10.1007/s40471-017-0131-y
   Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679. doi:10.1002/sim.6607
   PubMed Web of Science ®Google Scholar
• Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9(4):700–710. doi:10.1111/j.1538-7836.2011.04214.x
   PubMed Web of Science ®Google Scholar
• Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2015;13(3):360–369. doi:10.1111/jth.12828
   PubMed Web of Science ®Google Scholar
• Tagliaferri A, Feola G, Molinari AC, et al. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thromb Haemost. 2015;114(1):35–45. doi:10.1160/th14-05-0407
   Web of Science ®Google Scholar
• Ay C, Perschy L, Rejtö J, Kaider A, Pabinger I. Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting. Ann Hematol. 2020;99(12):2763–2771. doi:10.1007/s00277-020-04250-9
   Web of Science ®Google Scholar
• National Health Insurance Administration Ministry of Health and Welfare. Medication Reimbursement Guideline of Taiwan National Health Insurance Program; 2022. Available from: https://mohwlaw.mohw.gov.tw/FINT/FINTQRY04.aspx?starDate=00000000&endDate=99991231&no=&n1=&n2=&kt=&kw=%e5%87%9d%e8%a1%80%e5%9b%a0%e5%ad%90&kw2=&kw3=&kw4=&valid=3&type=etype_&RowNo=20. Accessed Aug 28, 2022.
   Google Scholar
• Dunkley S, Lam JCM, John MJ, et al. Principles of haemophilia care: the Asia-Pacific perspective. Haemophilia. 2018;24(3):366–375. doi:10.1111/hae.13425
   PubMed Web of Science ®Google Scholar
• Fischer K, Steen Carlsson K, Petrini P, et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood. 2013;122(7):1129–1136. doi:10.1182/blood-2012-12-470898
   PubMed Web of Science ®Google Scholar
• Feldman BM, Rivard GE, Babyn P, et al. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Lancet Haematol. 2018;5(6):e252–e260. doi:10.1016/s2352-3026(18)30048-6
   PubMed Web of Science ®Google Scholar
• Jun SNL, Testa D, Cox-Buckley B, Jain N. Characterization of women and girls with hemophilia treated in the US from A claims database; 2017.
   Google Scholar